Mereo BioPharma Group plc Income Statement
MREO|3 years of annual SEC 10-K data (FY2023-FY2025)
Line items include revenue, cost of goods sold, gross profit, operating expenses, interest, taxes, and net income with per-share data across 3 fiscal years. All figures from audited SEC 10-K filings.
Mereo BioPharma Group plc reported $500,000 in revenue and $42M in net loss for FY2025. Revenue decreased 95.0% from FY2023 to FY2025.
Based on SEC 10-K filings.
Key Data Points
- Altman Z-Score -7.87 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| Revenue | $500.0K | $0 | $10.0M |
| SG&A Expense | $23.0M | $26.4M | $18.4M |
| R&D Expense | $17.8M | $20.9M | $17.4M |
| Operating Income | -$40.1M | -$47.4M | -$28.4M |
| Interest Expense | $255.0K | $1.4M | $2.9M |
| Income Tax | $0 | $0 | -$532.0K |
| Net Income | -$41.9M | -$43.3M | -$29.5M |
| EPS (Basic) | -$0.06 | -$0.04 | -$0.07 |
| EPS (Diluted) | -$0.06 | -$0.04 | -$0.07 |
| Shares Outstanding | 739.6M | 659.5M | 603.2M |
| Operating Margin | -8021.4% | - | -284.2% |
| Profit Margin | -8375.6% | - | -294.7% |